Column Richard Hatzfeld

Flipping the Script on Cancer Prevention

More than five thousand Americans are diagnosed with cancer on any given day. Let that sink in for a moment. There’s a high likelihood that someone you know or love – possibly even you, personally – hears three of the most dreaded words possible: You have cancer.

Even in the age of advanced diagnostics, proton beam and nanotechnology treatments, and more walkathons than we can count, cancer still kills roughly one-third of those in the U.S. diagnosed with it. The numbers for low-income countries are far more shocking.

The causes of many cancers aren’t some hidden mystery. In the U.S., we can prevent two of the most dangerous forms of skin cancer by 40-50 percent by wearing sunscreen, but it’s an expensive option, and only 13 percent say they protect themselves most of the time with SPF-rated lotions. People are 15-30 times more likely to get lung cancer if they smoke; nevertheless, 1 in 10 Americans still smoke cigarettes.

You Have Cancer – or Not

We continue to lose many of the battles we should win against cancer. Billions of dollars have been spent over the years to educate the public on how they can prevent cancer; billions more have gone into treating patients. And then there’s the emotional toll that comes from hearing those three words.

There is a massive bright spot in this story, however. While the chances of preventing many forms of cancer with known interventions are frequently below 50 percent, we have a way of preventing six forms of cancer with a 90 percent effectiveness rate. It doesn’t come from adhering to daily rituals or resisting tempting vices. These cancers can be prevented by going to a doctor’s office or a pharmacy* and getting vaccinated against Human Papilloma Virus (HPV).

The catch is that the greatest chance of preventing HPV-related cancers later in life comes from vaccinating kids between 9-14. That requires parents seeing the importance of preventing HPV and many don’t, especially in southern states, where the number of pre-teens and adolescents who are fully vaccinated against HPV frequently falls below 50 percent.

Anxiety Versus Information

Many parents cite the vaccine’s safety as a leading concern, which is not based on fact. In the 17 years since the HPV vaccine has been available, more than 160 studies in multiple countries have shown no major adverse events associated with the vaccine. Instead, safety concerns have been fueled by misinformation on the Internet and skepticism among key audiences, including some healthcare professionals (HCPs).

More strikingly, however, the roots of hesitancy to vaccinate against HPV may go back to how it has been presented to patients: as a vaccine for sexually transmitted infections (STIs), not cancer. This is a major reason many parents discount the importance of getting their 10-year-old child vaccinated. In the face of such resistance, many HCPs in chronically under-vaccinated communities do not proactively recommend HPV vaccination during annual well visits.

Need to Reinform the Link Between HPV and Cancer

Reorienting this trend requires a concerted effort to flip the script on HPV vaccination discussions from STI prevention to cancer prevention. In the past year, only 22 percent of online conversations linked HPV with cancer. And in research conducted last month, FINN Partners found that only 46 percent of HCPs surveyed discuss HPV as cancer prevention.

This presents an important opportunity to close one of our generation’s most important health gaps. Healthcare professionals rank among the most trusted people in the U.S. When doctors make a vaccine recommendation with authority; most parents follow that counsel.

Flipping the script on HPV conversations tackles several significant barriers for patients: many may have omission bias, which means they believe vaccinating puts their kids in greater danger than the disease it’s supposed to prevent. And since they can’t picture their children getting an STI, they discount HPV vaccination further as a priority. But presenting that same vaccine as cancer prevention could change the nature of the conversation. Most parents understand cancer and see it as a threat. And cancer doesn’t carry the same stigma among many patient communities as sexually transmitted diseases.

The Cancer Prevention Message is Long Neglected

It’s time to make cancer prevention the dominant message in HPV vaccination decisions. More than 135 million doses of the HPV vaccine have been administered in the U.S., and we have seen a dramatic correlation in the drop in HPV cases: the prevalence of four HPV strains has declined by 88 percent among women aged 14-19. If HCPs are provided with better resources and more people are educated on HPV vaccination as cancer prevention, we have a shot at addressing misinformation about vaccine safety and continuing the upward trend of HPV vaccination.

The stakes are high for us to get this right. Because the only thing possibly worse than being told “You have cancer” is hearing that your son or daughter has HPV-related cancer later in life when it could have been prevented by a simple, safe decision to vaccinate them against HPV as an adolescent.

*HPV vaccines can be administered to adolescents at pharmacies in 22 states. Most states allow pharmacists to administer HPV to older patients.


Medika Life has provided this material for your information. It is not intended to substitute for the medical expertise and advice of your health care provider(s). We encourage you to discuss any decisions about treatment or care with your health care provider. The mention of any product, service, or therapy is not an endorsement by Medika Life

Richard Hatzfeld
Richard Hatzfeld
Richard Hatzfeld is a global communications leader and public health champion who has led campaigns in Africa, Asia, Europe and the Americas to confront many of the most urgent health issues of our time. Richard is a senior partner at Finn Partners, leading the firm's global public health group from Washington, DC. He was previously a senior leader at Ogilvy, where he advised multinational companies, foundations and NGOs on global health issues, including infectious and parasitic diseases, maternal and child health, immunization, pandemic preparedness, and antimicrobial resistance. Before Ogilvy, Richard was communications director at the Sabin Vaccine Institute and led communications activities for their vaccine development, infectious disease and advocacy efforts, as well as the Global Network for Neglected Tropical Diseases and its award-winning END7 Campaign. Richard began his global public health career pioneering the development of the first reproductive health product line and a nationwide network of maternal/child clinics in the Democratic Republic of the Congo on behalf of USAID.

Richard Hatzfeld

Richard Hatzfeld is senior partner, Global Public Health at FINN Partners. During his 25-year career, Hatzfeld has lived and worked in Africa, Asia, Europe and North America on behalf of governments, multinational companies, foundations and NGOs. He joins FINN after five years as a global team lead at Ogilvy, where he supervised multi-national vaccine communication efforts. Prior to Ogilvy, he was the communications director at the Sabin Vaccine Institute, overseeing communications for its vaccine development and advocacy efforts, as well as for the Global Network for Neglected Tropical Diseases and Sabin's award-winning END7 Campaign.

Connect with Richard




All articles, information and publications featured by the author on thees pages remain the property of the author. Creative Commons does not apply and should you wish to syndicate, copy or reproduce, in part or in full, any of the content from this author, please contact Medika directly.